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Abstract
Introduction The inducible nitric oxide synthase (iNOS) plays a
crucial role in early sepsis-related microcirculatory dysfunction.
Compared to a catecholamine therapy we tested effects of a
specific iNOS-inhibitor (1400W) on the microcirculatory
function in the brain.
Methods Seventy SD-rats (280-310 g) were divided into 1
control and 6 sepsis groups. Sepsis groups received 1 or 5 mg/
kg lipopolysaccharide (LPS) intravenously to induce a moderate
or severe sepsis syndrome. Thirty minutes later rats were further
randomized into subgroups receiving moderate volume therapy
alone or additionally continuous norepinephrine (NE) or 1400W
infusion. Separately, effects of 1400W on neurofunctional
parameters were investigated in 3 rats without sepsis induction.
Performing electric forepaw-stimulation evoked potentials (N2-
P1 amplitude, P1-latency) and local hemodynamic responses
were recorded with surface electrodes and laser Doppler over
the somatosensory cortex at baseline and repeatedly after LPS
administration. Cytokine levels (tumor necrosis factor-alpha
(TNFα), interleukin-6 (IL6), interferon-gamma (IFNγ)) and cell
destruction markers (neuron-specific enolase (NSE), S-100
calcium binding protein B (S100B)) were obtained at the end of
experiments.
Results During sepsis progression resting cerebral blood flow
increased and functionally activated hemodynamic responses
decreased in a dose-dependent manner. Whereas 1400W and
NE improved blood pressure, only 1400W stabilized resting
flow levels. However, both regimens were ineffective on the
functionally coupled flow responses and destruction markers
were similar between groups.
Conclusions NE and 1400W appeared to be ineffective in
mitigating the effects of sepsis on the neurovascular coupling.
Other regimens are needed to protect the cerebral
microcirculation under septic conditions.
Introduction
Sepsis and systemic inflammatory response syndromes are
the leading causes of mortality in intensive care units [1,2].
Overt nitric oxide (NO) production by the inducible form of
NO-synthases (iNOS) is assumed to play an important role in
early sepsis-related vasoregulative failure [3,4]. In response to
inflammatory stimuli NO levels increase rapidly within minutes
to hours [3,4] leading to hypotension [5-7] and refractoriness
to vasopressor catecholamines [8]. Animals treated with
selective iNOS-inhibitors or transgenic mice deficient in iNOS
showed less hypotension and increased microvascular reac-
tivity under septic conditions [9-11].
Regarding the cerebral circulation NO is intimately involved in
the adequate blood flow distribution under physiologic condi-
tions [12-14]. The excessive 100- to 1000-fold increase in NO
levels overrides the physiologic signals leading to a dissocia-
tion of the cerebral circulation. Although the overall perfusion
is increased (cerebral hyperemia) [7,15,16] it comes to a dys-
regulation on the microcirculative level [16,17]. As the brain is
very dependent on an appropriate blood supply the microcir-
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culatory failure was in part suggested to best explain the early
occurrence of sepsis-associated delirium [17,18].
Whereas catecholamines can restore the macrocirculation
there is growing evidence that they do not prevent the occur-
rence of microcirculatory dysfunction [19] Therefore, inhibition
of the iNOS might be an interesting therapeutic regimen in
sepsis syndromes. In this study, we compared protective
effects of a specific iNOS-inhibitor N-(3-(aminomethyl)ben-
zyl)acetamidine (1400W) with those of norepinephrine (NE)
on the cerebral microcirculation as evaluated by the neurovas-
cular coupling mechanism. To make comparison between a
moderate or severe sepsis syndrome 1 mg/kg or 5 mg/kg
lipopolysaccharide doses were given.
Materials and methods
General preparation
All procedures performed on the animals were in strict accord-
ance with the National Institutes of Health Guide for Care and
Use of Laboratory Animals and approved by the local Animal
Care and Use Committee.
Adult male SD-rats (weighing 280 to 310 g) were initially
anesthetized with 1.5 to 3% isoflurane in a 7:3 nitrous oxide
(N2O)/oxygen mixture of gases, tracheotomized, paralyzed
with pancuronium bromide (0.2 mg/kg/h), and artificially venti-
lated (Harvard Rodent Ventilator; Harvard, South Natick, MA,
USA). Arterial blood gas analyses and pH were measured
repeatedly as needed and at least every 30 minutes (Blood
gas analyzer model Rapidlab 348, Bayer Vital GmbH, Fern-
wald, Germany). Also, glucose and lactate levels were meas-
ured repeatedly (Glukometer Elite XL, Bayer Vital GmbH,
Fernwald, Germany; Lactate pro, Arkray Inc. European Office,
Düsseldorf, Germany). Glucose was kept in the physiologic
range by injections of 0.5 ml 20% glucose as needed. The
right femoral artery and vein were cannulated for blood pres-
sure recording, blood sampling, and drug administration. Rec-
tal body temperature was maintained at 37°C using a
feedback-controlled heating pad.
The head of the animals was fixed in a stereotaxic frame, the
apex of the skull was exposed, and the bone over the left pari-
etal cortex was thinned with a saline-cooled drill to allow tran-
scranial laser-Doppler flowmetry (LDF) [20]. The laser probe
(BRL-100, Harvard Apparatus, Holliston, MA, USA) was
placed 3.5 mm lateral and 1 mm rostral to the bregma in
accordance with the coordinates of the somatosensory cortex;
this location corresponds closely to the region of maximal
hemodynamic response during contralateral forepaw stimula-
tion [21-23]. The laser-Doppler signal and the systemic mean
arterial blood pressure were recorded continuously and proc-
essed on a personal computer running a data acquisition soft-
ware (Neurodyn, HSE, March-Hugstetten, Germany). As the
laser Doppler measures flow changes rather than absolute val-
ues, resting LDF signals are given in arbitrary units. However,
evoked signal changes can be used to assess flow changes
and are given in percent-changes from baseline [21,22].
Somatosensory stimulation was carried out with electrical
pulses applied by small needle electrodes inserted under the
skin of the right forepaw (PSM Module 676, HSE, March-Hug-
stetten, Germany). Electric brain activity was recorded monop-
olarily with an active calomel electrode at 0.5 mm behind the
laser probe and an indifferent calomel electrode placed on the
nasal bone. Signals were recorded and amplified (BPA Mod-
ule 675, HSE, March-Hugstetten, Germany) and somatosen-
sory evoked potentials (SEP) were averaged using the
Neurodyn acquisition software (HSE, March-Hugstetten, Ger-
many). Evoked potential amplitudes were calculated from the
N2-P1-amplitude differences and the latency between the
start of stimulation and occurrence of the P1-peak was
obtained.
Approximately 60 minutes before the stimulation experiments,
isoflurane/N2O anesthesia was discontinued and replaced by
intravenous application of α-chloralose (80 mg/kg; Sigma-
Aldrich Chemie GmbH, Taufkirchen, Germany). Supplemen-
tary doses of chloralose (30 mg/kg) were given every hour.
During chloralose anesthesia, the animals were ventilated with
a nitrogen/oxygen mixture of 1/1.
Neurovascular coupling measurement
Somatosensory activation was carried out by electrical stimu-
lation of the right forepaw with rectangular pulses of 0.3 ms
width and a repetition frequency of 2 Hz for 30 seconds. The
stimulation current was kept constant at 1.5 mA so that sys-
temic blood pressure changes did not occur [21-23]. Allowing
a rest of 30 seconds after each stimulation train, activation-
rest cycles were repeated 10 times to increase signal to noise
ratio. Flow velocity responses were averaged and relative
responses were calculated in relation to the resting phase, set-
ting the resting phase to zero. The evoked flow velocity
responses were calculated from the averaged relative flow
velocity signals under conditions of stimulation.
Clinical chemistry
At the end of the experiments blood samples were drawn into
tubes containing aprotinin (Trasylol, Bayer AG, Leverkusen,
Germany), immediately centrifugated and separated, after
which plasma was stored at -80°C until analyses. The neuron-
specific enolase (NSE) levels were determined using an
ELISA (NSE EIA kit; Hoffmann-La Roche, Basel, Switzerland).
The S-100B protein was determined with an immunolumino-
metric assay (Sangtec 100 LIA; Sangtec Medical, Bromma,
Sweden) using monoclonal antibodies specific for the beta
subunit of the S-100 protein. Cytokine analysis were per-
formed for IL-6, TNFα, interferon (IFN) γ using commercialized
rat ELISA sets (BD Bioscience, Heidelberg, Germany).Available online http://ccforum.com/content/13/4/R139
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Study design
Each 10 rats were subjected to one of the following groups:
control, 1 mg/kg LPS (LPS Escherichia coli, O111:B4,
Sigma-Aldrich Chemie GmbH, Germany), 5 mg/kg LPS, 1 mg/
kg LPS + 1400W, 1 mg/kg LPS + NE, 5 mg/kg LPS +
1400W, 5 mg/kg LPS + NE. LPS was dissolved in 0.5 ml
0.9% sodium chloride (NaCl). LPS was given within two to
three minutes. The control group received 0.5 ml vehicle. A
moderate volume therapy of 1 to 6 ml/kg/h 0.9% NaCl was
allowed in all groups. Thirty minutes after sepsis induction
1400W was given as a bolus of 7.5 mg/kg followed by a con-
tinuous infusion at a rate of 7.5 mg/kg/h. NE was given in
doses between 0.01 and 10 μg/kg/min to stabilize mean
blood pressure in the lower physiologic range between 90 and
100 mmHg.
Prior to and then after LPS administration SEPs, evoked and
resting cerebral blood flow velocity levels and blood pressure
were measured up to 270 minutes.
In an additional group (n = 3), we investigated the effects of
the same dose of 1400W without sepsis induction in healthy
rats.
Statistics
If appropriate, a two-way analysis of variance was performed
to assess differences within and between groups. In case of
significance a Fischer post-hoc test was applied. If assump-
tions of normal distribution and equality of variances could not
be assured, a nonparametric Friedman test was undertaken
instead (Statview, SAS, Cary, NA, USA). The significance level
was set to P < 0.05.
Results
No rat died from LPS injection. Table 1 shows the group aver-
aged data for partial pressure of carbon dioxide, pH, glucose,
lactate, and hemoglobin content. Partial pressure of oxygen
levels remained in the range of 240 to 250 mmHg in all groups
throughout experiments and therefore were not specified in
the table. Table 2 indicates the group data for blood pressure
together with the resting LDF signal, N2-P1 potential ampli-
tude, P1 latency, and evoked flow velocity response. The
cytokines as well as the cell destruction markers are given in
Table 3.
In non-septic rats, 1400W did not result in changes in the fol-
lowing data: blood pressure (121 ± 11 vs.125 ± 6 mmHg; not
significant), glucose levels (60 ± 9 vs.57 ± 6 mmol/L; not sig-
nificant), resting cerebral blood flow (135 ± 25 vs. 142 ± 28;
not significant), evoked flow responses (20 ± 7 vs. 20 ± 8%;
not significant), SEP amplitudes (16 ± 6 vs.15 ± 4 μV; not sig-
nificant), or P1-latencies (10 ± 2 vs.10 ± 1 ms; not significant).
General findings
With LPS-administration, rats developed signs of a severe
sepsis syndrome characterized by a considerable drop in
blood pressure (1 mg/kg LPS: 63 ± 10 mmHg; 5 mg/kg LPS:
56 ± 11 mmHg), occurrence of metabolic acidosis (1 mg/kg
LPS: 7.48 ± 0.04; 5 mg/kg LPS: 7.46 ± 0.04), and an
increase in the lactate levels (1 mg/kg LPS: 2.5 ± 0.8; 5 mg/
kg LPS: 2.4 ± 0.7 mmol/l) as indicated in Table 1. Cytokine
levels increased in all sepsis groups without differences
between groups (Table 3). Resting flow levels were signifi-
cantly induced in both LPS + NE groups by approximately
50%, whereas 1400W remained neutral (Table 2). Compared
with non-treated groups NE improved blood pressure levels
effectively in both groups (95 ± 17 mmHg and 92 ± 15
Table 1
Group averaged data for glucose, lactate, pH, pCO2 and hemoglobin for all groups
Glucose (mg/dL) Lactate (mmol/L) pH pCO2 (mmHg) Hemoglobin (mg/l)
Base End Base End Base End Base End Base End
Control 78 ± 12 82 ± 8 - 0.7 ± 0.7 7.57 ± 0.06 7.53 ± 0.05 32.6 ± 4.5 33.5 ± 2.2 137 ± 7 135 ± 6
1 mg/kg 89 ± 18 55 ± 9*** - 2.5 ± 0.8*** 7.53 ± 0.05 7.48 ± 0.04* 34.5 ± 5.1 32.8 ± 2.2 137 ± 6 124 ± 15*
5 mg/kg 74 ± 19 46 ± 15*** - 2.4 ± 0.7*** 7.51 ± 0.05 7.46 ± 
0.04***
35.5 ± 4.1 32.3 ± 1.7 133 ± 9 122 ± 15**
1 mg/kg. + 
NE
85 ± 15 68 ± 14* - 1.4 ± 0.4*** 7.52 ± 0.05 7.48 ± 0.05* 35.4 ± 4.0 34.3 ± 3.1 139 ± 10 119 ± 19**
5 mg/kg + NE 76 ± 14 70 ± 23 - 1.5 ± 0.6*** 7.52 ± 0.03 7.46 ± 0.05** 34.8 ± 3.2 32.8 ± 2.5 145 ± 12 122 ± 17**
1 mg/kg + 
1400W
78 ± 14 51 ± 7*** - 2.5 ± 0.6*** 7.53 ± 0.06 7.46 ± 0.09** 36.4 ± 4.8 35.2 ± 2.6 142 ± 12 121 ± 18**
5 mg/kg + 
1400W
73 ± 15 46 ± 8*** - 2.4 ± 0.4*** 7.52 ± 0.03 7.46 ± 
0.04***
34.8 ± 3.4 34.3 ± 1.4 139 ± 9 120 ± 15**
Data are given as mean ± standard deviation (SD) together with statistical results. Significance is given as: * P < 0.05; ** P < 0.01; *** P < 0.001 
compared with baseline. 1400W = N-(3-(aminomethyl)benzyl)acetamidine; NE = norepinephrine; pCO2 = partial pressure of carbon dioxide.Critical Care    Vol 13 No 4    Rosengarten et al.
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Table 2
Group averaged data for mean blood pressure, somatosensory evoked potentials, P1 latencies, evoked flow velocity responses, 
and resting LDFV signal, for the different time points of the experiment
Baseline 30 min 60 min 120 min 180 min 240 min 270 min
Mean BP (mmHg) Control 108 ± 12 108 ± 9 101 ± 12 103 ± 11 104 ± 14 108 ± 18 107 ± 14
Mean BP (mmHg) 1 mg/kg 110 ± 11 84 ± 13*** 65 ± 8*** 66 ± 10*** 62 ± 12*** 56 ± 9*** 63 ± 10***
Mean BP (mmHg) 5 mg/kg 115 ± 10 83 ± 17*** 62 ± 7*** 61 ± 12*** 54 ± 14*** 50 ± 7*** 56 ± 11***
Mean BP (mmHg) 1 mg/kg +NE 108 ± 12 84 ± 14*** 99 ± 12 92 ± 11 97 ± 11 94 ± 15 95 ± 15
Mean BP (mmHg) 5 mg/kg +NE 104 ± 10 79 ± 13*** 93 ± 19 90 ± 13 94 ± 12 94 ± 16 92 ± 13
Mean BP (mmHg) 1 mg/kg +1400W 106 ± 13 79 ± 18*** 80 ± 7** 83 ± 10** 85 ± 10** 79 ± 10*** 82 ± 12***
Mean BP (mmHg) 5 mg/kg +1400W 110 ± 11 73 ± 16*** 77 ± 11** 81 ± 8** 82 ± 10** 78 ± 13*** 76 ± 12***
SEP (μV) Control 21 ± 4 20 ± 5 21 ± 5 21 ± 5 20 ± 4 20 ± 4 20 ± 4
SEP (μV) 1 mg/kg 21 ± 7 18 ± 6 15 ± 5** 15 ± 4*** 12 ± 3*** 13 ± 3*** 12 ± 4***
SEP (μV) 5 mg/kg 20 ± 5 18 ± 5 15 ± 5** 15 ± 5*** 13 ± 4*** 10 ± 3*** 7 ± 2***
SEP (μV) 1 mg/kg +NE 21 ± 4 18 ± 4 18 ± 3* 17 ± 3** 16 ± 3** 16 ± 3** 16 ± 3**
SEP (μV) 5 mg/kg +NE 21 ± 7 17 ± 4 15 ± 4** 15 ± 4*** 13 ± 2*** 12 ± 2*** 14 ± 3***
SEP (μV) 1 mg/kg +1400W 22 ± 3 18 ± 3 11 ± 2*** 11 ± 2*** 10 ± 2*** 9 ± 2*** 9 ± 1***
SEP (μV) 5 mg/kg +1400W 21 ± 3 17 ± 4 11 ± 2*** 11 ± 2*** 10 ± 1*** 10 ± 2*** 10 ± 2***
P1 latency (ms) Control 11 ± 1 11 ± 1 11 ± 2 11 ± 1 12 ± 1 11 ± 1 12 ± 1
P1 latency (ms) 1 mg/kg 11 ± 0.4 11 ± 1 12 ± 1* 12 ± 1 12 ± 1 12 ± 2 13 ± 1
P1 latency (ms) 5 mg/kg 11 ± 1 12 ± 1 12 ± 1* 12 ± 2 12 ± 1 13 ± 2 13 ± 2
P1 latency (ms) 1 mg/kg +NE 12 ± 0.5 12 ± 1 12 ± 1 12 ± 1 12 ± 1 12 ± 1 12 ± 1
P1 latency (ms) 5 mg/kg +NE 11 ± 1 12 ± 0.4 12 ± 0.5* 12 ± 2 12 ± 1 12 ± 1 14 ± 3
P1 latency (ms) 1 mg/kg +1400W 12 ± 0.5 13 ± 1** 14 ± 1*** 14 ± 1*** 15 ± 2*** 15 ± 3*** 15 ± 2**
P1 latency (ms) 5 mg/kg +1400W 12 ± 0.5 13 ± 1** 14 ± 1*** 14 ± 1*** 14 ± 1*** 14 ± 1*** 15 ± 1*
EFVR (%) Control 20 ± 8 20 ± 6 20 ± 5 16 ± 6 17 ± 5 17 ± 4 18 ± 4
EFVR (%) 1 mg/kg 22 ± 10 14 ± 7 10 ± 4** 10 ± 4* 10 ± 4** 11 ± 5** 10 ± 5***
EFVR (%) 5 mg/kg 24 ± 7 16 ± 7 7 ± 2*** 6 ± 2** 5 ± 2*** 6 ± 2*** 4 ± 2***
EFVR (%) 1 mg/kg +NE 23 ± 7 18 ± 6 16 ± 10 14 ± 10 11 ± 8** 10 ± 7*** 9 ± 6***
EFVR (%) 5 mg/kg +NE 23 ± 7 14 ± 6 10 ± 7** 5 ± 3*** 3 ± 3*** 4 ± 3*** 5 ± 4***
EFVR (%) 1 mg/kg +1400W 18 ± 5 16 ± 8 8 ± 4*** 7 ± 3** 6 ± 2*** 5 ± 4*** 5 ± 3***
EFVR (%) 5 mg/kg +1400W 24 ± 7 20 ± 10 7 ± 4*** 8 ± 5** 7 ± 5*** 6 ± 3*** 5 ± 4***
Resting LDF (U) Control 176 ± 49 166 ± 38 170 ± 39 178 ± 33 178 ± 35 183 ± 32 186 ± 32
Resting LDF (U) 1 mg/kg 167 ± 60 180 ± 66 185 ± 70 200 ± 95 201 ± 94 203 ± 101 213 ± 110
Resting LDF (U) 5 mg/kg 145 ± 25 149 ± 44 132 ± 35 143 ± 37 153 ± 50 166 ± 58 193 ± 84
Resting LDF (U) 1 mg/kg +NE 153 ± 57 140 ± 38 187 ± 63 220 ± 96 243 ± 90* 248 ± 92 258 ± 82*
Resting LDF (U) 5 mg/kg +NE 162 ± 41 174 ± 57 170 ± 51 208 ± 58 231 ± 55 247 ± 79 267 ± 81*
Resting LDF (U) 1 mg/kg +1400W 171 ± 45 156 ± 47 170 ± 90 176 ± 53 185 ± 61 195 ± 63 190 ± 85
Resting LDF (U) 5 mg/kg +1400W 141 ± 48 120 ± 40* 128 ± 39 140 ± 58 140 ± 47 141 ± 41 157 ± 47
Data are given as mean ± standard deviation. Statistical results to baseline are given as: * P < 0.05, ** P < 0.01,*** P < 0.001. BP = blood 
pressure; EFVR = evoked flow velocity responses; LDF = laser-Doppler flowmetry; SEP = somatosensory evoked potentials.Available online http://ccforum.com/content/13/4/R139
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mmHg; both P < 0001 to non-treated groups). Not as effec-
tive as NE 1400W also stabilized blood pressure levels in both
groups (82 ± 12 and 76 ± 12 mmHg; both P < 0.001 vs. non-
treated animals).
Noteworthy is that only in the 1400W groups glucose substi-
tutions were necessary to maintain adequate blood glucose
levels. NE led to even higher glucose levels as compared with
the 1 mg/kg or 5 mg/kg LPS groups.
Neurofunctional findings
Addressing neurofunctional parameters NE was shown to be
most effective on N2-P1 amplitudes. Compared with the 1
mg/kg LPS group, evoked potential amplitudes were signifi-
cantly higher throughout experiments (270 minutes: 16 ± 3 μV
vs. 12 ± 4 μV; P < 0.05; Figure 1). In the 5 mg/kg group, NE
prevented a progressive decline of amplitudes at the end of
experiments (270 minutes: 14 ± 3 μV vs. 7 ± 2 μV; P < 0.001;
Figure 2). No protective effects were seen on the P1-latencies
or evoked flow velocity responses (Table 2).
1400W led to an early and progressive decline in evoked
potential amplitudes, which exceeded changes seen in the 1
mg/kg or 5 mg/kg LPS groups (Figures 1 and 2). Similarly, P1-
latencies increased to a higher extent as expected from non-
treated LPS groups (Table 2). Evoked flow velocity responses
dropped in relation to the decrease in evoked potential ampli-
tudes indicating still intact coupling. This makes the possibility
of an artifact in electrical recordings unlikely.
Discussion
The functionally coupled blood flow responses are decreased
during early phases of sepsis, which could contribute to brain
dysfunction (sepsis-associated delirium, septic encephalopa-
thy) in sepsis. Neither 1400W nor NE improved the neurovas-
cular coupling. However, interpretation of the effects of the
iNOS-inhibition on the neurovascular coupling is hampered by
the direct adverse effects of 1400W on SEP, which were only
seen under septic conditions. In both LPS groups, potential
amplitudes declined and latencies increased directly after
administration of the iNOS-inhibitor. In non-septic rats neither
1400W nor other unspecific NO-inhibitors showed this effect
[24,25]. A second new finding was the strong glucose lower-
ing effect of 1400W under septic conditions. From the litera-
ture a beneficial effect was anticipated because increased NO
levels adversely interfere with the mitochondrial function and
the intracellular glucose homeostasis [26,27]. However,
occurrence of mitochondrial respiratory chain enzyme dys-
function was shown to occur at later stages beginning six to
eight hours after sepsis induction [28,29]. Due to a tight glu-
Table 3
Data from cytokine and destruction marker measurements as group averaged data ± standard deviation
NSE ng/l S-100B ng/ml IL 6 pg/ml TNF-α pg/ml IFN-γ pg/ml
Control 0.29 ± 0.14 0.63 ± 0.3 93 ± 28 60 ± 22 32 ± 3
5 mg/kg LPS 1.8 ± 0.9 13 ± 8.6 5498 ± 1980 1868 ± 977 1600 ± 540
5 mg/kg LPS+1400W 1.6 ± 0.9 11 ± 9.7 4998 ± 1780 1655 ± 877 1800 ± 820
5 mg/kg LPS +NE 2.2 ± 0.4 10 ± 7.6 5300 ± 1654 1285 ± 592 1960 ± 660
Compared with control destruction markers and cytokine levels significantly increased in the sepsis groups but did not differ between sepsis 
groups.
1400W = N-(3-(aminomethyl)benzyl)acetamidine; IFN = interferon; IL = interleukin; LPS = lipopolysaccharide; NE = norepinephrine; NSE = 
neuron specific enolase.
Figure 1
Time course of group averaged N2-P1 amplitudes given as mean ±  standard deviation for the 1 mg/kg lipopolysaccharide groups Time course of group averaged N2-P1 amplitudes given as mean ± 
standard deviation for the 1 mg/kg lipopolysaccharide groups.  Nore-
pinephrine (NE) was protective on the potential amplitudes whereas 
selective inducible nitric oxide synthase (iNOS)-inhibition (N-(3-(ami-
nomethyl)benzyl)acetamidine (1400W)) showed adverse effects. Sta-
tistical results are given as compared to the non-treated group; * P < 
0.05. SEP = somatosensory evoked potentials.Critical Care    Vol 13 No 4    Rosengarten et al.
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cose control in the present study simple hypoglycemia cannot
explain our findings.
The effect of NE on evoked potential amplitudes cannot be
taken as a clear indication for neuroprotection. An improve-
ment of amplitudes is a direct effect of NE, which has been
described even under non-septic conditions [30]. It was
explained by a more focused activation of cortical neuronal
fields. In line with this interpretation, the oxidative metabolism
of the brain did not change in septic patients under NE treat-
ment [31]. The lack of an effect on the cell destruction markers
also points against a significant neuroprotective effect.
Regarding the cerebral circulation, NE is neutral as long as the
blood-brain barrier is intact and exerts vasoconstrictive effects
in case of a barrier leakage [32,33]. Therefore, the induced
cerebral blood flow in the NE group could be best explained
by the higher blood pressure levels. We also did not find an
effect of NE on the neurovascular coupling. This is shown in
Figure 3 which illustrates the relation between evoked poten-
tial amplitudes (x-axis) and resultant flow velocity changes (y-
axis) from the beginning to end of experiments. Arrow 1 shows
the typical initial uncoupling with a drop in evoked flow velocity
responses but still intact evoked potential amplitudes. This
response was not modified by NE as compared with non-
treated groups. Arrow 2 shows the succeeding drop in evoked
potential amplitudes, which were prevented in the NE group
possibly due to a substance effect. The typical pattern of an
initial uncoupling and succeeding drop in potentials was more
pronounced in the 5 mg/kg groups as compared with the 1
mg/kg groups.
Chloralose is a narcotic agent which allows neurophysiologic
monitoring [34]. It results in a mild alkalosis which explains the
higher initial pH levels.
We chose a classic catecholamine therapy, although immu-
nomodulatory effects of some catecholamines were reported
in the literature [35,36]. We did not find a significant effect of
NE on the cytokine level and also did not find significant
effects on the gene expression levels of chemokines [37]. Our
data are therefore in line with others who found epinephrine
but not NE to modulate cytokine levels in a porcine model of
endotoxic shock [38].
The cell destruction markers NSE and S-100 calcium binding
protein B have been widely used to assess the prognosis and
outcome of different disease processes [39-41]. A limitation
occurs in case of a blood-brain barrier breakdown because
serum levels then can considerably vary between individuals.
A similar study excluded a blood-brain barrier breakdown for
Figure 2
Time course of group averaged N2-P1 amplitudes given as mean ±  standard deviation for the 5 mg/kg lipopolysaccharide groups Time course of group averaged N2-P1 amplitudes given as mean ± 
standard deviation for the 5 mg/kg lipopolysaccharide groups.  Nore-
pinephrine (NE) was protective on the potential amplitudes at the end 
of experiments whereas selective inducible nitric oxide synthase 
(iNOS)-inhibition (N-(3-(aminomethyl)benzyl)acetamidine (1400W)) 
showed again adverse effects from beginning of therapy. Sttistical 
results are given as compared with the non-treated group; * P < 0.05; 
*** P < 0.001.
Figure 3
Graph of group averaged evoked potential amplitudes and evoked flow  velocity responses to illustrate the temporal aspects of neurovascular  dysfunction Graph of group averaged evoked potential amplitudes and evoked flow 
velocity responses to illustrate the temporal aspects of neurovascular 
dysfunction.  With lipopolysaccharide (LPS) application it comes first to 
a disproportional high decline in evoked laser-Doppler responses in 
both LPS dose groups (arrow 1) before somatosensory evoked poten-
tial amplitudes declined (arrow 2). This constellation indicates early 
microcirculatory failure in the septic brain. Whereas norepinephrine 
(NE) did not modify the drop in hemodynamic responses (arrow 1) it 
was protective on the evoked potential amplitudes (absent (1 mg/kg) or 
diminished (5 mg/kg) component of arrow 2). LDF = laser-Doppler 
flowmetry; SEP = somatosensory evoked potentials.Available online http://ccforum.com/content/13/4/R139
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the first hours of a sepsis syndrome [33]. This is reflected by
the narrow standard deviation of cell destruction markers.
Conclusions
Neurovascular coupling is decreased during early phases of
sepsis. This could contribute to brain dysfunction in sepsis
(sepsis-associated delirium). Neither NE nor 1400W consid-
erably prevented the breakdown of the neurovascular cou-
pling. However, further research is needed to clarify the direct
adverse effects of 1400W on neuronal function, which occurs
only under septic conditions.
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